98%
921
2 minutes
20
Background: African-American men are disproportionately burdened with colorectal cancer (CRC). Research is scarce on the social determinants that may influence CRC screening as the primary strategy for early detection among African-American males.
Methods: African-American men over the age of 18 years ( = 558) were recruited from a community health fair and anonymously surveyed about their health and cancer screening behaviors. A social ecological theoretical framework was utilized to identify intrapersonal, interpersonal, organizational, and community predictors of CRC screening, which may be associated with social determinants of health and health behaviors. Analysis included correlations and logistic regression.
Results: The mean age of participants was 54.3 years with 85.8% of men being over 40 years of age. Regarding CRC screening: 50.5% ( = 282) of African-American male participants had received any type of CRC screening at any time. Positive predictors of CRC screening included: health insurance status, older age, having spoken with a health provider about family cancer risk, and having a regular doctor. However, employment status and poor self-rated health were negative predictors of the outcome.
Conclusions: Social determinants of health, such as healthcare access and interactions with health systems, along with employment play a critical role in facilitating CRC screening completion in high-risk underserved populations such as African-American men.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280015 | PMC |
http://dx.doi.org/10.1016/j.jomh.2012.09.003 | DOI Listing |
Public Health
September 2025
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Objectives: Participation rates in fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening differ across socio-demographic subgroups. The largest health gains could be achieved in subgroups with low participation rates and high risk of CRC. We investigated the CRC risk within different socio-demographic subgroups with low participation in the Dutch CRC screening program.
View Article and Find Full Text PDFCancer Pathog Ther
September 2025
Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad 211004, India.
Background: Colorectal cancer (CRC) is a complex, heterogeneous disease characterized by frequent relapses and metastasis. Previous studies have reported that the invasion and progression of CRC in several cases can be controlled by targeting fusion genes. This study aimed to screen for potent fusion transcripts as potential molecular biomarkers and therapeutic targets for metastatic CRC (mCRC) using an approach.
View Article and Find Full Text PDFBioimpacts
August 2025
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Ankara 06330, Türkiye.
Colorectal cancer (CRC) constitutes a significant global health challenge, accounting for a considerable proportion of cancer cases and associated mortality. Projections indicate a potential increase in new cases by 2040, attributed to demographic factors such as aging and population growth. Although advancements in the understanding of CRC pathophysiology have broadened treatment options, challenges such as drug resistance and adverse effects persist, highlighting the necessity for enhanced diagnostic methodologies.
View Article and Find Full Text PDFCancer Rep (Hoboken)
September 2025
Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Background And Objectives: Colorectal cancer (CRC) screening and early detection reduce mortality. Curative treatment is based on surgical resection, and pathological analysis plays a key role in management. In Lebanon, the impact of the COVID-19 pandemic on healthcare has been compounded by an unprecedented socio-economic crisis in 2020.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of General Surgery, Beijing Tongren Hospital, Beijing, China.
This study investigates the clinical value of plasma Septin-9 gene methylation (mSEPT9) and carcinoembryonic antigen (CEA) in colorectal cancer (CRC), and their correlations with clinicopathological features and recurrence. A retrospective study included 81 CRC patients (observation group) and 73 healthy controls (comparison group) from January 2021 to January 2023, with pathological diagnosis as the gold standard. Plasma mSEPT9 (via quantitative PCR) and CEA (via electrochemiluminescence) levels were measured.
View Article and Find Full Text PDF